Journal of Lipid and Atherosclerosis最新文献_第3页

Association Between Nut Consumption and Metabolic Syndrome in Korean Adults. 韩国成年人食用坚果与代谢综合征的关系

Journal of Lipid and Atherosclerosis Pub Date : 2025-05-01 Epub Date: 2025-05-12 DOI: 10.12997/jla.2025.14.2.219

Sunhye Shin

{"title":"Association Between Nut Consumption and Metabolic Syndrome in Korean Adults.","authors":"Sunhye Shin","doi":"10.12997/jla.2025.14.2.219","DOIUrl":"10.12997/jla.2025.14.2.219","url":null,"abstract":"Objective: Although nuts have been reported to lower the risk of multiple diseases, evidence regarding their effect on metabolic syndrome (MetS) in Asian populations is limited. Therefore, this study aimed to clarify the association between nut consumption and the risk of MetS.Methods: A cross-sectional analysis was conducted using data from the seventh Korea National Health and Nutrition Examination Survey (2016-2018). MetS was defined according to the guidelines of the National Cholesterol Education Program Adult Treatment Panel III. Responses to a single 24-hour dietary recall from 4,365 younger adults (19-39 years), 7,498 middle-aged adults (40-64 years), and 4,378 older adults (≥65 years) were analyzed using multivariable logistic regression models.Results: In this study, based on the culinary definition, nuts included tree nuts and peanuts. Approximately 25% of Korean adults were found to consume nuts. After adjusting for confounding variables, including age, body mass index, total energy intake, household income, alcohol consumption, smoking, aerobic exercise, and energy from carbohydrates, nut consumption was associated with a lower risk of MetS among middle-aged men (40-64 years; odds ratio [OR], 0.68; 95% confidence interval [CI], 0.53-0.88), older men (≥65 years; OR, 0.72; 95% CI, 0.53-0.98), and older women (≥65 years; OR, 0.69; 95% CI, 0.53-0.89).Conclusion: These results suggest that consuming nuts may exert protective effects against MetS in middle-aged Korean men and older Korean adults.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 2","pages":"219-228"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategies to Optimize Recovery in Frail Patients With Cardiovascular Disease Through Exercise-Based Cardiac Rehabilitation. 通过以运动为基础的心脏康复优化虚弱心血管疾病患者康复的策略

Journal of Lipid and Atherosclerosis Pub Date : 2025-05-01 Epub Date: 2025-04-03 DOI: 10.12997/jla.2025.14.2.159

Kyuwan Lee

{"title":"Strategies to Optimize Recovery in Frail Patients With Cardiovascular Disease Through Exercise-Based Cardiac Rehabilitation.","authors":"Kyuwan Lee","doi":"10.12997/jla.2025.14.2.159","DOIUrl":"10.12997/jla.2025.14.2.159","url":null,"abstract":"Cardiovascular disease (CVD) remains a critical global health challenge, with frailty in older adults further exacerbating the risk of adverse outcomes. Exercise-based cardiac rehabilitation (EBCR) offers a promising approach to improving cardiovascular function, reducing mortality, and enhancing quality of life in individuals with CVD. However, frail patients often encounter unique barriers, including reduced muscle strength, impaired mobility, and logistical challenges, which hinder their participation in traditional EBCR programs. Resistance training has been shown to improve muscle strength, balance, and functional independence while reducing fall risk, making it a key intervention for frail individuals. Aerobic exercise, when introduced gradually, further enhances cardiovascular endurance and overall resilience. Telehealth exercise strategies can provide an effective means of overcoming logistical barriers by fostering adherence and enabling real-time adjustments to exercise regimens, despite challenges such as digital literacy. This narrative review highlights innovative strategies integrating personalized exercise regimens and telehealth solutions to address the unique needs of frail patients. By prioritizing adaptable, accessible, and evidence-based strategies, an evolved EBCR approach holds the potential to significantly improve long-term health outcomes and quality of life for this vulnerable population.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 2","pages":"159-173"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid. 新的降脂剂：Inclisiran和benpedoic酸2024 KSoLA更新。

Journal of Lipid and Atherosclerosis Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.12997/jla.2025.14.2.135

Hack-Lyoung Kim, Jung-Joon Cha, Sang-Hak Lee

{"title":"2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid.","authors":"Hack-Lyoung Kim, Jung-Joon Cha, Sang-Hak Lee","doi":"10.12997/jla.2025.14.2.135","DOIUrl":"10.12997/jla.2025.14.2.135","url":null,"abstract":"Inclisiran and bempedoic acid (BA) are non-statin lipid-lowering agents that have been approved for use in the US and Europe. Inclisiran, a subcutaneously administered small interfering RNA targeting proprotein convertase subtilisin/kexin type 9 messenger RNA, is effectively delivered to the liver via lipid nanoparticles and conjugation. In several phase 3 trials, it has successfully reduced low-density lipoprotein cholesterol (LDL-C) by 50% and has an acceptable safety profile. Currently, the results of clinical outcome studies are awaited. While it is indicated for both primary and secondary cardiovascular prevention, it is selectively recommended after statin-based regimens. BA, an oral inhibitor of adenosine triphosphate-citrate lyase, decreases cholesterol production and enhances LDL uptake by hepatocytes. This enzyme is absent in muscle cells, and BA has fewer muscle-related adverse events. In clinical trials, it lowered LDL-C by 17%-21% compared to placebo and showed a clinical outcome benefit in patients with statin intolerance. This agent modestly increases the incidence of gout and cholelithiasis. For primary and secondary prevention, it may be recommended as a non-first-line agent, either alone or in combination therapy.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 2","pages":"135-144"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cholesterol and Cardiovascular Risk in Type 2 Diabetes: The Role of Kidney Function. 2型糖尿病的胆固醇和心血管风险：肾功能的作用。

Journal of Lipid and Atherosclerosis Pub Date : 2025-05-01 Epub Date: 2025-04-09 DOI: 10.12997/jla.2025.14.2.190

Ji-Hyun Kim, Seung-Hwan Lee, Kyu Na Lee, Kyungdo Han, Mee Kyoung Kim

{"title":"Cholesterol and Cardiovascular Risk in Type 2 Diabetes: The Role of Kidney Function.","authors":"Ji-Hyun Kim, Seung-Hwan Lee, Kyu Na Lee, Kyungdo Han, Mee Kyoung Kim","doi":"10.12997/jla.2025.14.2.190","DOIUrl":"10.12997/jla.2025.14.2.190","url":null,"abstract":"Objective: The association of lipid parameters with cardiovascular disease (CVD) and the impact of kidney function on this association have not been thoroughly evaluated in patients with type 2 diabetes mellitus (T2DM).Methods: Using the Korean National Health Insurance Service Cohort database, we identified 2,343,882 subjects with T2DM in 2015-2016. Baseline lipid levels and kidney function were evaluated and followed up until December 2020. Subjects were classified into three groups according to their estimated glomerular filtration rate (eGFR): ≥60, 30-59, or <30 mL/min/1.73 m2. We analyzed the diabetes group with eGFR ≥60 and low-density lipoprotein cholesterol (LDL-C) <70 mg/dL as a reference group.Results: The risk of CVD began to increase at LDL-C ≥100 mg/dL in the eGFR ≥60 mL/min/m2 group. The risk of CVD in the eGFR 30-59 mL/min/m2 group was increased by 43%, even in the LDL-C <70 mg/dL, and the risk increased progressively with LDL-C category. Among subjects with eGFR 30-59 mL/min/m2, LDL-C 70-99, 100-129, 130-159, and ≥160 mg/dL were significantly associated with the risk of CVD, with hazard ratio (95% confidence interval) of 1.48 (1.43-1.53), 1.54 (1.49-1.60), 1.55 (1.48-1.63), and 1.88 (1.77-2.00), respectively. In the eGFR <30 mL/min/m2 group, a 3.3-fold increased risk of CVD was seen, even at LDL-C <70 mg/dL.Conclusion: The cutoff levels of LDL-C that increase CVD risk in patients with T2DM depend on kidney function, which influences the relationship between LDL-C and CVD risk in patients with T2DM.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 2","pages":"190-199"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144258252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Lipoprotein (a) Levels and Coronary Artery Disease (CAD) Among Patients With or Without CAD Family History. 在有或没有冠心病家族史的患者中，脂蛋白(a)水平与冠心病（CAD）的关系

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-12-26 DOI: 10.12997/jla.2025.14.1.120

Hayato Tada, Nobuko Kojima, Kan Yamagami, Yasuaki Takeji, Kenji Sakata, Soichiro Usui, Masa-Aki Kawashiri, Masayuki Takamura

{"title":"Association Between Lipoprotein (a) Levels and Coronary Artery Disease (CAD) Among Patients With or Without CAD Family History.","authors":"Hayato Tada, Nobuko Kojima, Kan Yamagami, Yasuaki Takeji, Kenji Sakata, Soichiro Usui, Masa-Aki Kawashiri, Masayuki Takamura","doi":"10.12997/jla.2025.14.1.120","DOIUrl":"10.12997/jla.2025.14.1.120","url":null,"abstract":"Objective: Lipoprotein (a) (Lp[a]), which is a highly heritable trait, is associated with coronary artery disease (CAD). However, the insight into whether the association between Lp(a) and CAD differs according to the family history of CAD remains unclear.Methods: We investigated clinical data of 4,512 participants who underwent serum Lp(a) level measurement at Kanazawa University Hospital between 2008 and 2016. The association between Lp(a) and CAD according to CAD family history was investigated through logistic regression analyses.Results: CAD family history and Lp(a) levels were significantly associated with CAD development (odds ratio [OR], 1.32; 95% confidence interval [CI], 1.12-1.52; p<0.001 and OR, 1.13; 95% CI, 1.03-1.23; p<0.001 per 10 mg/dL, respectively). In patients without CAD family history, those with Lp(a) levels ≥30 mg/dL had higher CAD risk than those with Lp(a) levels <30 mg/dL (reference) (OR, 1.33; 95% CI, 1.05-1.61; p<0.001). In patients with CAD family history, those who had Lp(a) levels <30 and ≥30 mg/dL were both highly at risk for CAD (OR, 1.24; 95% CI, 1.04-1.44; p<0.001 and OR, 1.68; 95% CI, 1.34-2.02; p<0.001, respectively). Adding CAD family history and Lp(a) information to other conventional risk factors enhanced CAD risk discrimination (C-statistics: 0.744 [0.704-0.784] to 0.768 [0.730-0.806], and 0.791 [0.751-0.831], respectively; p<0.05 for both).Conclusion: Lp(a) level was associated with CAD development regardless of CAD family history status.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"120-127"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardioprotective Effects of Adiponectin-Stimulated Autophagy. 脂联素刺激的自噬对心脏的保护作用。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-11-07 DOI: 10.12997/jla.2025.14.1.40

Eddie Tam, Mireille Ouimet, Gary Sweeney

{"title":"Cardioprotective Effects of Adiponectin-Stimulated Autophagy.","authors":"Eddie Tam, Mireille Ouimet, Gary Sweeney","doi":"10.12997/jla.2025.14.1.40","DOIUrl":"10.12997/jla.2025.14.1.40","url":null,"abstract":"Cardiovascular diseases (CVDs), including heart failure, pose a significant economic and health burden worldwide. Current treatment strategies for heart failure are greatly limited, in that they mainly mitigate symptoms or delay further progression. In contrast, therapies aimed at proactively preventing the onset of heart failure could greatly improve outcomes. Adiponectin is an adipocyte-derived hormone that confers an array of cardioprotective effects. It exerts anti-inflammatory effects, improves metabolic function, mitigates endothelial cell dysfunction, and reduce cardiomyocyte cell death. Furthermore, it has gained increasing attention for its ability to activate autophagy, a conserved cellular pathway that facilitates the degradation and recycling of cell components. The disruption of autophagy has been linked to CVDs including heart failure. Additionally, growing evidence also points to specific forms of autophagy, namely mitophagy and lipophagy, as crucial adaptive responses in protection against CVDs. The protective effects of adiponectin, autophagy, mitophagy, and lipophagy against CVDs along with potential therapeutic implications will be discussed.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"40-53"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chylomicron Characteristics Are Associated With Microsomal Triglyceride Transfer Protein in an Animal Model of Diet-Induced Dysbiosis. 在饮食诱导的生态失调动物模型中，乳糜微粒特征与微粒体甘油三酯转移蛋白相关。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-11-14 DOI: 10.12997/jla.2025.14.1.106

Carolina Olano, Gregorio Fariña, Morena Wiszniewski, Jimena Medel, Celina Morales, Silvia Friedman, Vanesa Macri, Magalí Barchuk, Gabriela Berg, Laura Schreier, Valeria Zago

{"title":"Chylomicron Characteristics Are Associated With Microsomal Triglyceride Transfer Protein in an Animal Model of Diet-Induced Dysbiosis.","authors":"Carolina Olano, Gregorio Fariña, Morena Wiszniewski, Jimena Medel, Celina Morales, Silvia Friedman, Vanesa Macri, Magalí Barchuk, Gabriela Berg, Laura Schreier, Valeria Zago","doi":"10.12997/jla.2025.14.1.106","DOIUrl":"10.12997/jla.2025.14.1.106","url":null,"abstract":"Objective: Intestinal remnant chylomicrons (CMs) are involved in cardiovascular residual risk and the atherogenic process. Microsomal triglyceride transfer protein (MTTP) catalyzes the assembly of lipids to apolipoprotein B48, generating CMs. Dysbiosis could alter this behavior. This study investigated the chemical composition of CMs and their associations with intestinal MTTP and gut fat depots in a diet-induced dysbiosis animal model.Methods: Male Wistar rats were fed either a standard diet (control, n=10) or a high-fat high-sucrose diet (HFSD, n=10) for 14 weeks. Measurements included serum glucose, lipid-lipoprotein profile, free fatty acids (FFAs), lipopolysaccharide (LPS) and the Firmicutes/Bacteroidetes (F/B) ratio in stool samples, via real-time quantitative polymerase chain reaction. Lipid content in isolated CMs (ultracentrifugation d <0.95 g/mL) was assessed, and MTTP, cell intestinal fat content (CIF), histology, apoB mRNA and tight junction (TJ) proteins were analyzed, in intestinal tissue.Results: Compared to control, HFSD rats showed higher levels of LPS, triglycerides (TGs), non-high-density lipoprotein cholesterol (HDL-C) levels, TG/HDL-C ratio, FFAs, and the F/B ratio. HFSD CMs showed increased TG and phospholipids. TJ proteins levels were lower in the HFSD group, while histological scores showed no differences. CIF was increased in the HFSD group. No significant differences in apoB mRNA were found. MTTP expression was higher in the HFSD group, and directly correlated with CM-TG and inversely correlated with CIF.Conclusion: Our findings imply that gut TG content may constitute an important determinant of the secretion of TG-rich CMs, promoted by MTTP, with increased atherogenic potential.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"106-119"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Journal of Lipid and Atherosclerosis in 2025: From Excellence to Eminence. 2025年的脂质和动脉粥样硬化杂志：从卓越到卓越。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2025-01-18 DOI: 10.12997/jla.2025.14.1.1

In-Kyung Jeong

引用次数: 0

Application of Generative Artificial Intelligence in Dyslipidemia Care. 生成式人工智能在血脂异常护理中的应用。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-12-10 DOI: 10.12997/jla.2025.14.1.77

Jihyun Ahn, Bokyoung Kim

{"title":"Application of Generative Artificial Intelligence in Dyslipidemia Care.","authors":"Jihyun Ahn, Bokyoung Kim","doi":"10.12997/jla.2025.14.1.77","DOIUrl":"10.12997/jla.2025.14.1.77","url":null,"abstract":"Dyslipidemia dramatically increases the risk of cardiovascular diseases, necessitating appropriate treatment techniques. Generative AI (GenAI), an advanced AI technology that can generate diverse content by learning from vast datasets, provides promising new opportunities to address this challenge. GenAI-powered frequently asked questions systems and chatbots offer continuous, personalized support by addressing lifestyle modifications and medication adherence, which is crucial for patients with dyslipidemia. These tools also help to promote health literacy by making information more accessible and reliable. GenAI helps healthcare providers construct clinical case scenarios, training materials, and evaluation tools, which supports professional development and evidence-based practice. Multimodal GenAI technology analyzes food images and nutritional content to deliver personalized dietary recommendations tailored to each patient's condition, improving long-term nutritional management for those with dyslipidemia. Moreover, using GenAI for image generation enhances the visual quality of educational materials for both patients and professionals, allowing healthcare providers to create real-time, customized visual aids. To apply successfully, healthcare providers must develop GenAI-related abilities, such as prompt engineering and critical evaluation of GenAI-generated data.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"77-93"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atherosclerotic Cardiovascular Disease in Cancer Survivors: Current Evidence, Risk Prediction, Prevention, and Management. 癌症幸存者的动脉粥样硬化性心血管疾病：目前的证据、风险预测、预防和管理。

Journal of Lipid and Atherosclerosis Pub Date : 2025-01-01 Epub Date: 2024-07-19 DOI: 10.12997/jla.2025.14.1.30

Arum Choi, Subin Kim, Seonji Kim, Iksung Cho, Min Jae Cha, Seng Chan You

{"title":"Atherosclerotic Cardiovascular Disease in Cancer Survivors: Current Evidence, Risk Prediction, Prevention, and Management.","authors":"Arum Choi, Subin Kim, Seonji Kim, Iksung Cho, Min Jae Cha, Seng Chan You","doi":"10.12997/jla.2025.14.1.30","DOIUrl":"10.12997/jla.2025.14.1.30","url":null,"abstract":"While advances in cancer treatment have led to improved survival rates, cancer survivors are at a significant risk of developing atherosclerotic cardiovascular disease (ASCVD). This review examines the risk, diagnosis, and prevention of ASCVD in this population. Cancer survivors, especially those diagnosed with certain types, face a significantly higher risk of developing ASCVD than the general population. We introduce the \"triad model\" to explain this increased risk of ASCVD among cancer patients. This model includes three interconnected components: common catalysts, cancer influence, and treatment impact. The factors contributing to this model are the shared risk factors between cancer and ASCVD, such as smoking, obesity, and systemic inflammation; the direct effects of cancer on cardiovascular health through chronic systemic inflammation and endothelial damage; and the significant effects of anticancer treatments, including chemotherapy and radiation, which can worsen cardiovascular complications and hasten the progression of ASCVD. Furthermore, cancer survivors are at a higher risk of developing and dying from ASCVD, highlighting the necessity for tailored guidelines and strategies for ASCVD prevention and management in this population. The review explores the utility of diagnostic tools, such as coronary artery calcium scoring, in predicting and managing ASCVD risk. It also emphasizes the importance of prevention strategies that include regular cardiovascular monitoring and lifestyle modifications. Finally, the relationship between cancer survival and cardiovascular health highlights the importance of integrated and comprehensive care approaches. Continued research, the development of prediction models, and specific preventative strategies are essential to improve cancer survivors' overall health outcomes.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"14 1","pages":"30-39"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0